Loxo Oncology Inc

Latest Loxo Oncology Inc News and Updates

  • uploads///Ignyta RD Expenses
    Company & Industry Overviews

    Inside Ignyta’s Financial Performance

    Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?

    In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Eli Lilly and Loxo: A Robust Oncology Pipeline for Future Years

    Eli Lilly’s acquisition of Loxo has added the FDA approved asset VITRAKVI and the early- and mid-stage oncology pipeline assets LOXO-305, LOXO-195, and LOXO-292.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Loxo Oncology Is Expected to Boost Eli Lilly’s Revenue in 2019

    Eli Lilly and Company (LLY) expects its Loxo Oncology (LOXO) acquisition to become revenue accretive starting in 2019.

    By Margaret Patrick
  • uploads///ARRY Revenue Trend
    Company & Industry Overviews

    Array BioPharma’s Financial Performance

    The total revenues of Array BioPharma (ARRY) decreased from $39.2 million in 1Q17 to $29.7 million in 1Q18.

    By Kenneth Smith
  • uploads///ARRY
    Company & Industry Overviews

    Array BioPharma’s ARRY-382 and ARRY-797

    Array BioPharma (ARRY) completed its Phase 1b clinical trial of its investigational drug candidate ARRY-382 in combination with Merck’s (MRK) Keytruda for advanced tumor indications.

    By Kenneth Smith
  • uploads///ARWR TRiM platform
    Company & Industry Overviews

    What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?

    Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.

    By Kenneth Smith
  • uploads///Hepatitis B virus life cycle
    Company & Industry Overviews

    Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases

    ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.

    By Kenneth Smith
  • uploads///ARWR Drug Pipeline
    Company & Industry Overviews

    Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

    Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.

    By Kenneth Smith
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.